Sale!

PRIUNTA 440

Name: PRIUNTA 440
Brand: Abbott India Ltd
SKU: 355
Availability: InStock

TRASTUZUMAB LYOPHILIZED 440MG

2-8* C

MRP	:	~~MRP ₹50,872.77~~
Price	:	₹15,000.00
You Save	:	₹35,872.77 (70.51%)

1 vial(s)

SKU: 355 Categories: Anti-Cancer, Anti-Cancer Drugs, CANCER Tags: ANTI CANCER, COLD CHAIN Brand: Abbott India Ltd

Priunta 440mg Injection contains Trastuzumab as its active constituent and is specifically indicated for use in HER2-positive breast cancer. In patients with HER2-positive status, breast cancer cells exhibit an overexpression of HER2 proteins, which act as signals promoting the rapid growth and development of cancerous tumors. This medication is also employed in the treatment of metastatic gastric cancer where increased levels of HER2 proteins are present.

HER2-positive breast cancers are recognized for their aggressive nature. The targeted therapy provided by Priunta 440mg Injection works by selectively targeting these specific HER2 proteins that are responsible for the growth, development, and spread of cancer cells. Due to potential risks, it is crucial to use effective birth control methods throughout the treatment period and for at least seven months following the final dose.

Priunta 440mg Injection is not recommended for patients under 18 years of age, or for those who have severe breathing problems or require oxygen treatment. It is essential to inform your physician if you have any history of heart problems, experience breathlessness, or have undergone any other cancer treatment previously. Furthermore, ensure you provide your physician with a complete list of all medicines, including supplements and herbal medicines, you are currently taking before commencing treatment with this medication.

Advanced and metastatic breast cancer
Metastatic gastric cancer

The protein known as HER2 (human epidermal growth factor receptor 2) is a crucial component in cell growth and division. In certain cancers, particularly HER2-positive breast and gastric cancers, this protein is found in abnormally large quantities on the surface of the cancer cells. This overexpression of HER2 acts as a powerful signal, continuously stimulating the cancer cells to grow and divide at an accelerated rate, thereby driving tumor proliferation and potentially making the cancer more aggressive.

Priunta 440mg Injection, which contains Trastuzumab, is a targeted therapy designed to counteract this overactive HER2 signaling. It works by selectively binding to the extracellular domain of the HER2 protein on the surface of the cancer cells. By attaching to HER2, Trastuzumab effectively blocks the protein's ability to send growth signals into the cell. This inhibition disrupts the downstream signaling pathways that are essential for cancer cell proliferation and survival.

In addition to directly blocking HER2 signaling, Trastuzumab is also believed to work through other mechanisms, such as mediating antibody-dependent cellular cytotoxicity (ADCC). In ADCC, the antibody (Trastuzumab) bound to the cancer cell's HER2 protein acts as a flag, attracting and enabling immune cells (like natural killer cells) to recognize and destroy the HER2-overexpressing cancer cells.

Through these combined actions—blocking growth signals and recruiting immune responses—Priunta 440mg Injection effectively stops the growth of cancer cells that are dependent on HER2 for their uncontrolled proliferation.

It is extremely important to provide your doctor with a complete and accurate list of all medications you are currently taking or have taken prior to starting treatment with Priunta 440mg Injection. This comprehensive list should include not only prescribed medications but also over-the-counter medicines, any nutritional or vitamin supplements, and all herbal products. The reason for this thorough disclosure is that certain medications can interact with Priunta 440mg Injection. Such interactions could potentially alter the effectiveness of the treatment or lead to undesirable side effects. Your doctor needs this information to identify and manage any potential interactions, thereby ensuring your safety and the optimal efficacy of your cancer therapy.

Priunta 440mg Injection shall either be administered before or after surgery.
It will be given as an Intravenous infusion for 90 minutes, if well tolerated it shall be administered within 30 minutes for the next doses.

Keep Priunta 440mg Injection out of sight and reach of children.
Store between 2˚C and 8˚C.

Serious

Heart Problems
Allergic reactions
Kidney problems
Breathing difficulties

Common

Fever
Visual disturbances
Nose bleeds or runny nose
Hair loss
Dizziness
Nail disorders
Weight loss
Loss of appetite
Bruising
Dry mouth
Liver inflammation
Muscle pain
Asthma/ lung disorders

Breast Feeding

Unsafe

Avoid breastfeeding your baby while on the treatment with Priunta 440mg Injection atleast for at least seven months after the final dose.

Alcohol

Consult Your Doctor

Consult your doctor to know if it is safe to consume alcohol while you are on treatment with Priunta 440mg Injection.

Liver

Consult Your Doctor

You need to tell your physician if you have any liver disorders before starting Priunta 440mg Injection as it requires dosage adjustment for severe liver impairment.

Lungs

Consult Your Doctor

Talk to your doctor if you have any lung conditions before starting treatment with Priunta 440mg Injection.

Driving

Unsafe

Priunta 440mg Injection can cause unusual tiredness and dizziness. Hence, it is advised to avoid driving or handling machinery during the treatment.

Pregnancy

Unsafe

Discuss with your physician before taking this Priunta 440mg Injection if you are pregnant or think you might be pregnant. Do not take this medicine during the pregnancy unless advised by the doctor to take as it may cause to the unborn baby.